Total Funding
21
49
Total FundingSeries A raised
Growth Score
-6 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
96182
Cytena develops single-cell printing technology for cell research and professional diagnostics.
Benjamin Steimle: CFO & Co-Founder
Thomas Kretschmann: Senior Field Application SpecialistPast Role: Qiagen, Senior Application Specialist
Cellink
About the Company
cytena GmbH has developed a device called cy-Clone to separate single cells. Single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research. The cy-Clone is supported by an automated imaging process to encapsulate cells in
droplets, which are delivered to any type of substrate. Thanks to this particularly gentle delivery method, the cells are able to survive post printing and can either be analyzed thereafter or grown into clonal colonies. To determine clonality, multiple images are recorded during the process. Cross-contamination is avoided by the use of disposable parts.
